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v. ABSTRACT 
Introduction: Comorbidities occur commonly in rheumatoid arthritis(RA) but little is 
known about their prevalence and spectrum in South Africans. 
Objectives: To determine the prevalence and associated risk factors of 
comorbidities in black South Africans with RA. 
Methods: A retrospective record review of black RA patients at a tertiary 
rheumatology service. The cumulative comorbidity score was assessed using the 
Charlson comorbidity score. 
Results: Of the 500 patients studied, the mean(SD) age and disease duration was 
60.0(11.1) and 10.7(5.0) years, respectively. Most patients (50.5%) had severe 
disability (functional class 3-4) at diagnosis with 98% of patients having had ≥1 
comorbidities. The median number of comorbidities was 3.0(IQR 2.0-4.0). 
Comorbidities were a function of age, follow up duration and disability (p=<0.001). 
The table below shows the common comorbidities.  
 
 Prevalence
(%) 
 Prevalence
(%) 
Anaemia  391(78.2) Tuberculosis  53(10.6) 
Hypertension 350(70.0) HIV (n=204) 44(9.3) 
Peptic ulcer disease 
(PUD)(n=114) 
73(64.0) Congestive heart failure  33(6.6) 
Hypercholesterolemia (n=466) 221(47.4) Cerebrovascular disease  14(2.8) 
Osteoporosis (n=132) 62(47.0) Malignancy  9(1.8) 
Diabetes mellitus  77(15.4) Ischaemic heart disease  3(0.6) 
Serious infections  56(11.2)   
 
Serious infections occurred more commonly in those with osteoporosis (OR-4.32), 
vasculitis (OR-4.0), anaemia (OR-3.62) and HIV (OR-2.32). Patients with the 
following comorbidities were more likely to have deceased during follow up: CCF 
(OR-5.44), serious infections (OR-4.58), interstitial lung disease (OR-3.91), 
arthroplasty (OR-2.46), TB (OR-2.22) and PUD (OR-1.54). 
 
Conclusion: Despite the high prevalence of cardiac risk factors in this population, 
the prevalence of ischaemic heart disease remains low. Osteoporosis is commonly 
found in RA patients undergoing DEXA scans.  
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1. CHAPTER 1: BACKGROUND  
1.1 Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease of synovial joints with a 
number of extra-articular manifestations. This results in a broad range of clinical 
manifestations, often making the management of patients challenging. Comorbidities 
are common amongst RA patients and pose their own challenges with respect to 
screening, disability, therapy, treatment choices, morbidity and mortality. An 
understanding of the spectrum of comorbid diseases and their associated risk 
factors, aids in managing the patient with RA holistically. Comorbid diseases are well 
described in industrialized populations. However local South African data are 
lacking. Due to a variety of reasons, including some differences in the clinical 
phenotype of RA in black South Africans coupled with specific socioeconomic, 
environmental and resource limitations, the spectrum and prevalence of 
comorbidities are likely to be different from industrialized countries. 
 
1.2 Rheumatoid arthritis 
1.2.1 Overview 
Rheumatoid arthritis is a chronic systemic inflammatory disease which primarily 
affects the synovial joints. It presents mostly as a symmetrical inflammatory 
polyarthritis affecting small joints of the hand. Poor or inadequate control of joint 
inflammation, often leads to joint destruction resulting in joint deformities with 
subsequent functional impairment (1). Rheumatoid arthritis has an insidious disease 
onset with early disease typically involving the small joints of the hands and feet.  
Due to the inflammatory nature of the disease patients commonly report early 
morning stiffness of the joints which lasts longer than an hour and improves with 
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physical activity. Despite the synovium being the central target of the disease, RA by 
virtue of its systemic nature, can be associated with a multitude of extra-articular 
manifestations. 
1.2.2 Epidemiology 
The prevalence of RA varies amongst nations with a worldwide prevalence in 
developed countries of 0.5 – 1%. These figures are influenced by geographical 
location, ethnicity and gender. Females are affected by the disease two to three 
times more commonly than men. Data from the United States of America (USA) 
have shown that although the disease is more prevalent with increasing age, the 
overall disease prevalence is decreasing in recent years (2).  
Earlier studies in black Africans suggested that RA was uncommon and had a mild 
course (3). More recent studies from predominantly urban populations, show a 
greater resemblance to Western populations with an increase in severity and 
prevalence of disease (4, 5). A systematic review of RA patients in Africa had 
estimated a much lower disease prevalence (0.36%) as compared to the 
approximated 1% in industrialized caucasian populations (6). Prevalence figures 
may be inherently lower in African populations due to younger populations, shorter 
life expectancy and under reporting of the disease. In addition, most South African 
data were collected during the apartheid era and was thus influenced by political 
divides and the effects of migrant labour. 
1.2.3 Aetiopathogenesis 
Although the precise aetiology of RA remains unknown, it is thought to be likely from 
a combination of genetic susceptibility and environmental triggers. This results in the 
activation of immune modulators and signaling pathways responsible for the clinical 
manifestations of the disease. 
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1.2.3.1 Genetic factors 
The association between RA and the human leukocyte antigen DRB1 (HLA-DRB1) 
has been well established. The majority of patients carry the HLA-DRB1*04 allele 
with individuals expressing two alleles being at a greater risk for extra-articular 
disease and nodulosis (7). A number of alleles conferring an increased risk have 
been identified in rheumatoid factor (RF) and anti-citrullinated peptide antibody 
(ACPA) positive patients. In contrast, genetic factors in seronegative disease are 
less well established but still play an important role. 
1.2.3.2 Environmental factors 
The environmental influence in the pathogenesis of the disease is supported by 
concordance rates of only 15-30% in monozygotic twins (8). Amongst patients with 
the HLA-DRB1 allele, smoking increases the risk of developing the disease. 
Moreover, this combination increases the risk of ACPA positive disease which 
confers a less favorable prognosis (9). Furthermore, recent work has demonstrated 
the importance of various gut microbiomes in the development and the progression 
of RA. Dysbiosis of gut microbiomes have been shown to correlate with auto-
antibodies and this microbiome imbalance is partly corrected with the use of disease 
modifying anti-rheumatic drugs (DMARDS)(10). Other environmental associations 
such as alcohol, oral contraceptives, vitamin D and red meat consumption lack 
supporting evidence (11). 
1.2.3.3 Immune modulators 
The synovium is the epicenter of disease in RA. Synovitis occurs as a result of 
leukocytic infiltration of the synovium. This is mediated by a variety of immune 
responses, cytokines and angiogenesis. The innate and adaptive immune systems 
both play key roles in this response with both cellular and humoral immunity being 
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implicated. The role of T cells is largely mediated by Th1 and Th17 T cells. Humoral 
immunity contributes to the pathogenesis of the disease by auto-antibody production, 
auto-antigen presentation and cytokine production (12).   
Several cytokines have been implicated in the disease with interleukin (IL) 1, IL-6, IL-
17, tumor necrosis factor (TNF) and vascular endothelial growth factor playing 
dominant roles. These cytokines are mediators of inflammation and cell migration. 
Activation of the innate immune system involves a number of effector cells including 
macrophages, neutrophils, mast cells and natural killer cells. Macrophages have a 
central role in the development of synovitis (12).  
In addition to synovitis, cartilage and bone destruction occurs via several mediators 
including matrix metalloproteinases and osteoclast activation. Moreover, pannus 
formation further leads to bone erosions. Angiogenesis, involving vascular 
endothelial growth factor, is important in pannus development and maintenance (12).  
1.2.4 Clinical features 
Rheumatoid arthritis usually has an insidious disease onset but can occasionally 
present in an acute or sub-acute manner. Any joint can be affected but the disease 
has a predilection for the metacarpophalangeal, metatarsophalangeal, proximal 
interphalangeal, wrist and knee joints. Disease is typically symmetrical and manifests 
as early morning stiffness, swelling, pain, tenderness, limitation of movement and 
deformities. This classically occurs in the hands and to a lesser extent in the feet. 
Typical deformities include boutonniere deformities, swan-neck deformities, ulnar 
deviation of the fingers, radial deviation of the wrists, Z deformities of the thumb, 
piano key deformities of the ulnar styloid, hallux valgus, hammer toes and flattening 
of the feet. Other musculoskeletal abnormalities include tenosynovitis and 
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entrapment neuropathies such as carpal tunnel syndrome. The disease may be 
associated with constitutional symptoms. 
1.2.5 Radiological features 
Radiologically, early disease may be limited to soft tissue swelling with the 
subsequent development of peri-articular osteopenia. As the disease progresses 
joint spaces narrow and juxta-articular erosions develop. Large cystic erosions may 
manifest in severe advanced disease (13). 
Additional imaging modalities such as MRI, grey scale and power Doppler 
ultrasonography are being increasingly utilized to detect early disease (13). Although 
clinically useful, these modalities are limited by their availability and cost. Both MRI 
and ultrasonography are useful in (even prior to their radiographic appearance on X-
rays) detecting early synovitis and joint damage. Furthermore, MRI is useful in 
demonstrating bone marrow oedema and synovial hypertrophy (13). 
Ultrasonography is a sensitive tool and thus useful for its negative predictive value 
(14). The addition of power Doppler ultrasonography has been proven to be a 
valuable marker of inflammation and disease activity (15). 
1.2.6 Extra-articular manifestations 
Risk factors for the development of extra-articular disease include smoking, 
rheumatoid factor positivity and an early onset of physical disability (16). The extent 
of involvement of extra-articular disease is illustrated in Table 1.1. The risk of 
developing a vasculitis in RA patients is increased with longstanding disease treated 
with glucocorticoids (as opposed to with DMARDs), strongly positive rheumatoid 
factor and smoking (17). Extra-articular disease in RA is a poor prognostic indicator 
and increases morbidity and mortality (18). 
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Table 1.1 - Extra-articular manifestations 
Cardiovascular disease: 
- Valvular heart disease 
- Myocarditis 
- Cardiomyopathies 
- Rheumatoid nodules 
Neurological disease: 
- Myelopathies 
- Sensorimotor neuropathies 
- Entrapment neuropathies 
 
Ocular disease: 
- Sicca syndrome 
- Episcleritis 
- Scleritis 
Dermatological manifestations: 
- Rheumatoid nodules 
- Skin ulcers  
- Neutrophillic dermatoses 
Vascular disease: 
- Vasculitis (digital infarcts, 
gangrene, cutaneous ulcers, 
livedo reticularis, purpura 
and visceral arteritis) 
Respiratory disease: 
- Pleuritis 
- Pleural effusions 
- Obstructive lung disease 
- Interstitial lung disease 
- Bronchiectasis 
- Pulmonary nodules 
Haematological abnormalities: 
- Anaemia 
- Felty’s syndrome 
(neutropaenia, splenomegaly 
and nodular RA) 
Secondary Sjogren’s syndrome 
Renal involvement 
 
1.2.7 Diagnosis 
There are no diagnostic criteria for RA. Instead classification criteria, which have 
been developed primarily for research purposes, are often used to make a clinical 
diagnosis of RA. The classification criteria have evolved over time with the earliest 
being the 1958 Rome criteria, followed by the American College of Rheumatology 
(ACR) 1987 criteria and most recently the 2010 ACR/EULAR (European League 
Against Rheumatism) classification criteria (19). The 2010 criteria have a better 
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sensitivity for early disease whereas the 1987 ACR criteria (20) have a better 
specificity for established disease. 
Table 1.2 - 1987 ACR criteria (20) 
1987 ACR criteria (At least 4 out the 7 criteria are needed for the classification of 
RA) 
1. Morning stiffness (at least one hour) (≥ 6 weeks) 
2. Arthritis in three or more joints (≥ 6 weeks) 
3. Hand joint arthritis (≥6	weeks) 
4. Symmetric arthritis (≥	6	weeks) 
5. Rheumatoid nodules 
6. Positive rheumatoid factor 
7. Radiographic changes (erosions or juxta-articular decalcification in the hands and 
wrists) 
 
Table 1.3 - 2010 ACR/EULAR criteria (19) 
2010 ACR/EULAR criteria (≥ 6/10 required for a definitive classification of RA 
1. Joint involvement  
            1 large joint 0 
            2-10 large joints 1 
            1-3 small joints (+/- involvement of large joints) 2 
            4-10 small joints (+/- involvement of large joints) 3 
            >10 joints (at least one small joint) 5 
2. Serology  
            Negative RF and negative ACPA 0 
            Low positive RF or ACPA (≤3 x upper limit of normal)  2 
            High positive RF or ACPA (>3x upper limit of normal) 3 
3. Acute phase reactants  
            Normal CRP and normal ESR 0 
            Abnormal CRP  or abnormal ESR 1 
4. Duration of symptoms  
            <6 weeks 0 
            ≥6 weeks 1 
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1.2.8 Treatment 
1.2.8.1 Principles of management 
Several principles including disease severity, response to medication and comorbid 
conditions govern the treatment of RA. Treatment encompasses pharmacological 
and non-pharmacological interventions (21). The treatment of RA has increasingly 
focused on early diagnosis and intervention. This is of importance to relieve 
symptoms, prevent damage and preserve function. Non-pharmacological 
interventions are largely aimed at improving functionality, quality of life and 
alleviating pain. They include occupational therapy, psychological support, 
education, functional aids and lifestyle modifications.  
Pharmacological treatment includes the early use of DMARDS. Glucocorticoids and 
nonsteroidal anti inflammatory drugs (NSAIDs) are used for initial symptomatic relief, 
adjunctive treatment in difficult to control patients, when changing DMARDs and with 
flares of disease (21). 
1.2.8.2 Disease modifying anti-rheumatic drugs 
Disease modifying anti-rheumatic drugs are comprised of two broad categories of 
agents, namely synthetic DMARDs and biological DMARDs. Synthetic agents 
include methotrexate, sulfasalazine, leflunomide and antimalarials. Biologic agents 
include TNF inhibitors (TNFi)(etanercept, adalimumab, infliximab), IL-6 receptor 
antagonists (tocilizumab), IL-1 antagonists (anakinra), anti-CD20 B cell antibodies 
(rituximab), T cell co-stimulation inhibitors (abatacept) and Jak inhibitors 
(tofacitinib)(21). 
Synthetic DMARDs are the initial drugs of choice with their use being guided by 
disease severity and comorbid disease. Methotrexate is commonly used as initial 
treatment and is used in combination with other DMARDs in moderate to severe 
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disease. These drugs can be used in combination with other synthetic or biological 
agents in difficult to control disease (21).  
1.2.8.3 Challenges to therapy 
Due to the complex nature of the disease, various challenges are encountered in 
clinical practice. Some of these challenges are directly related to therapy. These 
include the side effect profile of medications, drug interactions and drug availability. 
This is particularly pertinent to the South African setting with resource and financial 
constraints. Biologic agents are costly and rarely available in the state health care 
sector in South Africa. They are often limited to use in clinical trials. In addition, the 
high burden of infectious diseases, especially tuberculosis, demands the judicious 
use of DMARDs. 
 
1.3 Comorbidities in rheumatoid arthritis 
1.3.1 Comorbidities in the industrialized world 
Comorbidities are defined as diseases or disorders which occur in addition to the 
primary disease. They may occur incidentally, as a result of chronic inflammation or 
secondary to the physiological and psychological effects of the underlying disease 
process. In addition, they may develop as an indirect result of the treatment of RA. 
Comorbidities are common in RA patients in industrialized countries. In a United 
Kingdom (UK) study the baseline prevalence of one or more comorbidities in RA 
patients was 36% with a subsequent cumulative prevalence of 81% after 15 years 
(22). Patients with RA had on average 1.6 comorbidities with the number of 
comorbidities increasing with advancing age (22, 23). An Italian study showed that 
78.6% of RA patients who were admitted to hospital had one or more comorbidities 
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(24). The high cumulative number and individual prevalence of comorbidities may be 
a reflection of improved survival and the late age of diagnosis. 
A recent international cross sectional study evaluating comorbidities demonstrated a 
wide variation in their individual prevalence amongst differing nations (25). The study 
was carried out across 17 nations and demonstrated a high prevalence of 
depression, ischaemic cardiovascular disease, solid tumours and chronic obstructive 
pulmonary disease (COPD). This variability in the spectrum and prevalence of 
comorbid conditions is likely a reflection of genetic, ethnic and socioeconomic 
differences amongst nations. There is currently no local data on the prevalence of 
comorbidities in the South African rheumatoid population. Due to the high variability 
amongst differing nations, international data cannot necessarily be extrapolated to 
local populations. 
1.3.2 Impact of comorbidities in rheumatoid arthritis 
The impact of comorbidities in RA patients is multifaceted and should be carefully 
considered when managing the disease. The most drastic effect is the relationship 
between comorbidities and mortality. Comorbid diseases amongst RA patients 
increase mortality even after adjusting for other variables (22). With each additional 
comorbid condition, the risk of death increases. In established disease, numerous 
studies have shown an association between comorbidities and worsening levels of 
function and disability (22, 26, 27). Moreover, comorbidities have an economic 
impact. The overall expenditure on all forms of arthritis has increased in recent 
times. This, in part, can be attributed to the increase in the number of patients with 
comorbid conditions (28). 
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1.3.3 Charlson comorbidity score and index 
Quantifying the burden of comorbidities is of value in both clinical and research 
settings. Various tools have been developed to aid in quantifying this burden. One 
such tool is the Charlson comorbidity score (CCS) and the Charlson comorbidity 
index/probability (CCI). The CCS is determined by adding assigned scores to various 
comorbidities as well as assigning a score for every decade above the age of 50 
years. This cumulative score can be used to calculate the CCI which is a predictor of 
survival (29). The CCI has been validated for its ability to predict 10 year survival 
after adjusting for gender and disease states (30). It serves as an important research 
aid by quantifying comorbid disease thus allowing for comparisons to be drawn. Its 
clinical usefulness is in decision making of how aggressively to treat conditions in 
which various comorbidities coexist. The spectrum of comorbidities in RA is varied 
and for simplification can be grouped into the following systems: cardiovascular 
(CV), respiratory, psychiatric, infectious, malignancies, osteoporosis and 
gastrointestinal disease. 
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Table 1.4 - Charlson comorbidity score and index 
Charlson comorbidity score and index 
Myocardial infarction (1 point) COPD (1 point) 
Congestive heart failure (1 point) Peptic ulcer disease (1 point) 
Liver disease:  
- Mild (1 point) 
- Moderate to severe (3 points) 
Diabetes mellitus:  
Uncomplicated (1 point) 
Target organ damage (2 points) 
Cerebrovascular disease (1 point)  Peripheral vascular disease (1 point) 
Hemiplegia (2 points) Dementia (1 point) 
Moderate to severe renal disease  
(2 points)                           
Connective tissue disease - RA 
(1 point) 
Leukaemia (2 points) Lymphoma (2 points) 
Solid tumor (2 points) Metastatic disease (6 points) 
AIDS (6 points)  
Age:   
                 0 - 49 years (0 points)  
                 50 - 59 years (1 point)  
                 60 - 69 years (2 points)  
                 70 - 79 years (3 points)  
                 80 - 89 years (4 points)  
                 90 - 99 years (5 points)  
100+ years (6 points)  
  
CCI: 
- Y = e(ccs*0.9) e = 2.71828 
- Z = 0.983Y 
- Z = 10 year survival 
 
 
Legend: 
COPD - Chronic obstructive pulmonary disease 
AIDS – Acquired immune deficiency syndrome 
RA – Rheumatoid arthritis 
 
1.4 Specific comorbidities in rheumatoid arthritis 
1.4.1 Ischaemic heart disease 
Cardiovascular disease (CVD) has a marked impact on morbidity and is the most 
common cause of early mortality amongst RA patients in industrialized populations 
(31). The increase in CV related deaths in RA patients has been reported to be as 
high as sixty percent (32). Most of this risk is attributed to a twofold increased rate of 
myocardial infarction (MI)(33) with an increased likelihood of multi-vessel coronary 
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artery disease (CAD)(34). Silent MI and an increased risk of sudden cardiac death 
have also been reported (35). Despite advancements in treatment modalities and 
improved disease outcomes, mortality from CVD remains unchanged (32, 36). This 
highlights the need for an increased focus on CVD in RA in both clinical and 
research based settings.  
Both traditional and non-traditional risk factors play a role in the pathogenesis of 
atherosclerotic disease in RA. Some traditional risk factors such as insulin 
resistance, obesity, reduced physical activity and smoking may be more prevalent in 
RA patients. In contrast, the evidence around the prevalence of other traditional risk 
factors such as dyslipidaemia, diabetes mellitus (DM) and hypertension is conflicting 
(37). Furthermore, the impact that these risk factors have differs amongst different 
ethnic groups. For example, in black Africans obesity is not related to 
atherosclerosis, whereas in African white women body mass index and waist to hip 
ratios are related to common carotid artery thickness and plaques (38). Traditional 
risk factors in isolation do not account for the extent of CVD in RA.  
Endothelial dysfunction is postulated to play a significant role in atherosclerosis. The 
expression of adhesion molecules with subsequent monocyte adhesion accelerates 
and promotes atherosclerosis. Inflammatory mediators in RA such as C-reactive 
protein (CRP), IL-1 and TNF promote these adhesion molecules thereby enhancing 
atherosclerosis (39). Inflammatory mediators together with glucocorticoid use are 
associated with insulin resistance which further increases CV risk (37). 
Hypercoagulability mediated by fibrinogen, Von Willebrand factor, tissue factor and 
plasminogen activator inhibitor 1 also contribute to CAD in RA (40). In addition to the 
underlying inflammatory nature of the disease, drug therapy plays an integral role in 
the development of CVD in RA.  
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Glucocorticoid use for a period of more than 6 months at a medium dose, defined as 
an oral prednisone dose ≥7.5mg, is associated with a higher prevalence of 
hypertension (41). Glucocorticoid use at such doses are generally reserved for more 
severe disease however hypertension remains more prevalent even after adjusting 
for disease severity (41). The mechanism for this association is unclear and is 
thought to be multifactorial with increased arterial stiffness, increased vascular 
adrenergic sensitivity and renal mineralocorticoid effects playing a role. Selective 
cyclooxygenase 2 inhibitors and more recently non-selective NSAIDs, used to treat 
pain and inflammation in RA, have also been implicated in the development of 
hypertension and atherosclerotic disease through the inhibition of prostaglandins 
(42). Only methotrexate use is associated with a decreased CV mortality. This effect 
may be due to the protective anti inflammatory effect of the drug mediated through 
elevated adenosine levels (43). Treatment with TNFi has also been shown to 
improve endothelial dysfunction (44). 
1.4.2 Heart failure 
Rheumatoid arthritis is also associated with an increased risk for the development of 
congestive cardiac failure (CCF). A retrospective study showed a twofold increased 
risk of developing CCF amongst RA patients (45). Similar to CAD, this increased risk 
is thought to be multifactorial with traditional risk factors and drug therapy playing a 
role. This increased risk however, remains evident even after adjusting for traditional 
risk factors. Thus, mechanisms inherent to the underlying disease state are likely to 
be contributory. The link between heart failure and inflammation has been 
established. In RA, the effect of inflammation is further supported by the increased 
risk of heart failure seen in patients with elevated levels of IL-6, CRP and TNF (46). 
15 
 
1.4.3 Respiratory comorbidities 
Respiratory comorbidities are a major cause of death in RA patients. Recent studies 
have shown that mortality related to respiratory disease is increased twofold in 
women with RA (47). This risk is even greater amongst women with RF positive 
disease.  
Obstructive lung disease, in particular COPD, is more prevalent amongst American 
RA patients compared to the general population (48). The presence of obstructive 
lung disease in RA was associated with decreased survival rates. In the same study 
however, a decreased prevalence of asthma was noted amongst American RA 
patients. This is in contrast to a Taiwanese study which showed a significantly higher 
rate of asthma in RA (49). Although smoking may be more common amongst RA 
patients, obstructive lung disease occurs more frequently even after adjusting for 
smoking (48). T cell mediated responses are thought to play a role in respiratory 
disease. Smoking is thought to be a risk factor for the development of RA itself. Like 
CV comorbidities, the drugs used to treat RA have a significant impact on pulmonary 
disease.  
Drug induced lung injury has various manifestations including an increased likelihood 
of infections, inflammatory lung disease and fibrotic lung disease. Methotrexate has 
been associated with the progression of subclinical interstitial lung disease (ILD)(50). 
In addition, its use may result in the development of an acute hypersensitivity 
pneumonitis, interstitial fibrosis (less commonly), asthma or an increase in the 
development of lung nodules. Leflunomide is associated with a higher risk of 
developing ILD and an increased risk of acute pneumonitis in those with pre-existing 
lung disease (51). It too, may lead to worsening pulmonary nodular disease. The use 
of sulfasalazine in RA has been associated with pneumonitis, nonspecific interstitial 
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pneumonia, pleural effusions and granulomatous lung disease (52). Biological 
agents used in the treatment of severe RA may improve pulmonary disease however 
some biological TNFi agents may rarely induce ILD (53).  
1.4.4 Infections 
Infections are one the three leading causes of death amongst RA patients. A higher 
incidence of serious or hospital requiring infections occur in RA patients. A twofold 
increased risk of serious infections is seen in RA compared to age matched non-RA 
patients (54). This is of particular concern amongst developing nations like South 
Africa with a high burden of infectious diseases such as HIV and tuberculosis 
(TB)(55). The increased risk of serious infections is likely a consequence of immune 
dysfunction, comorbid conditions and drug therapy. 
Deficiencies in multiple components of the innate immune system may occur in RA 
patients. A neutropaenia can develop as a consequence of anti-neutrophil antibodies 
(56). In addition to a decrease in absolute neutrophil numbers, the neutrophils are 
functionally impaired with increased margination and apoptosis being observed (56). 
Gene mutations affecting complement factor 5 may also play a role in innate immune 
dysfunction. The adaptive immune system is also inept, thereby contributing to the 
increased risk of serious infections in RA. Thymic dysfunction as well as a decrease 
in the diversity of T cell receptors are seen in RA. This results in a subsequent 
decrease in the ability to recognize pathogenic antigens (57).  
Comorbid conditions such as chronic lung disease, COPD, chronic kidney disease 
(CKD) and DM confer an increased risk to the development of infections. Other risk 
factors such as smoking and a higher degree of physical impairment are also 
contributory. 
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The use of glucocorticoids and other immunosuppressive therapies in the 
management of RA further impairs the immune system. Evidence relating to the 
susceptibility of developing infections with glucocorticoid use, points towards a dose 
dependent relationship. Doses of oral prednisone of >5mg/day are associated with a 
greater risk of infection (58, 59). Treatment with TNFi impairs immune response 
through the impaired activation of macrophages. Studies relating their use to the 
development of infections have shown various results. Randomized control trials 
have shown an increased risk for the development of serious infections with an odds 
ratio of 1.2 – 1.4. Observational studies however, have shown a decrease in the 
relative risk of serious infections over time (56). The development of TB is of 
particular concern with the use of TNFi. In contrast methotrexate confers a minimal 
risk to the development of serious infections (60). This is likely due to its 
immunosuppressive effects being offset by improved immune function achieved with 
control over inflammation. 
1.4.5 Malignancy 
The overall risk of malignancy in patients with RA remains unchanged compared to 
the general population. A site specific risk for malignancy is however seen. This risk 
is likely accounted for by a number of factors including underlying chronic 
inflammation, drug therapy, comorbid diseases and environmental factors. A meta-
analysis of 21 publications demonstrated an increased risk of lymphoma and lung 
cancer amongst RA patients with a decrease in the incidence of colorectal and 
breast cancer (61).  
The risk of lymphoma is increased twofold in RA with most of this risk accounted for 
by Hodgkin’s lymphoma (61). Chronic inflammation, immune activation, decreased 
natural killer cell activity and decreased T suppressor lymphocyte activity is thought 
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to contribute to this increased risk. The risk of developing lung cancer in RA is 
increased by 1.5 to 3.5 times compared to the general population (61). Cigarette 
smoking is an established risk factor for the development of lung cancer, however 
the increased risk of lung cancer in RA persists even after adjusting for smoking 
(62). In addition inflammation and ILD are also contributing factors to the risk of 
malignancy (62).  
The use of NSAIDs has a protective effect against the development of colorectal 
cancer and this effect may account for the reduced risk seen amongst RA patients 
(61). Azathioprine, methotrexate and alkylating agents may play a contributory role in 
developing malignancies especially lymphoma although evidence for this is uncertain 
(61). Furthermore, data regarding the risk of development of malignancies with the 
use of TNFi is contradictory. Several meta analyses have shown an increased risk of 
malignancy however observational studies have not demonstrated this same risk 
(61). The role of other confounding factors like chronic inflammation, comorbid 
diseases, severity of disease and other past or present medications make the 
pathogenic role of TNFi difficult to assess. 
1.4.6 Gastrointestinal comorbidities 
Gastrointestinal comorbidities in RA occur largely as a result of drug therapy with the 
most commonly implicated drug class being the NSAIDs. A wide spectrum of 
gastrointestinal diseases including gastritis, peptic ulcer disease (PUD), duodenal 
ulcers and oesphagitis are commonly seen amongst RA patients as a result of 
NSAIDs and glucocorticoid use. Patients affected with these conditions commonly 
present with dyspepsia, bleeding ulcers and/or perforation. Admissions with the 
above, although common, have decreased over time with admission rates of 0.5% in 
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the year 2000 (63). This is likely as a result of more judicious NSAIDs use as well as 
the use of proton pump inhibitors. 
In addition to PUD, intestinal inflammation may also occur as a result of increased 
intestinal permeability with NSAID use. This may have a variety of clinical 
manifestations including intestinal perforations, bleeding and small bowel 
obstruction. Glucocorticoid use has also been associated with a higher rate of 
gastrointestinal perforations (64).  
Hepatic dysfunction in RA patients may occur as a result of a drug induced hepatitis, 
autoimmune hepatitis, viral hepatitis or fatty liver disease. Viral based etiologies for 
the development of RA have been suggested with hepatitis B and C viruses being 
previously implicated in its pathogenesis (65). Maillefert et al have however, shown 
that the prevalence of hepatitis C in French RA patients (0.65%) was the same as in 
the general population (66). This finding suggests that the association between 
hepatitis C infection and RA is unlikely.  
Hepatitis C may masquerade as RA by presenting with an arthritis thus posing a 
diagnostic challenge. Clifford et al have shown that a positive RF is seen in 76% of 
hepatitis C infected patients (67). The arthritis in hepatitis C infection is unlike RA in 
that it is a non-destructive, mono or oligoarthritis with a predisposition for large and 
medium sized joints. TNFi use in concomitant RA and hepatitis C does not seem to 
result in an increase in viral replication or worsening of disease (68). 
Drug induced hepatic damage may also occur with a number of agents used in the 
treatment of RA. These agents include methotrexate, leflunomide, sulfasalazine and 
NSAIDs. As such, concomitant hepatic disease in RA patients calls for the judicious 
use of these drugs with regular careful monitoring for drug related liver toxicity.  
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1.4.7 Osteoporosis 
Peri-articular osteoporosis (OP), seen radiologically, is a prominent feature of RA. In 
addition to localized bone loss, general bone loss occurs commonly (69). 
Osteoporosis increases the risk of fractures and vertebral deformities in these 
patients. The prevalence of OP, as well as its associated risk factors, varies widely 
amongst differing nations (70). Bone loss is attributed to a number of contributory 
factors. Underlying immune activation with subsequent cytokine and inflammatory 
mediator activation results in the differentiation and recruitment of osteoclasts. 
Osteoclast activity increases bone resorption resulting in OP. Gough et al 
demonstrated a relationship between higher CRP levels and increased bone loss 
thus suggesting a relationship between the degree of inflammation and bone loss 
(70). In further work done by Gough et al, early RA and higher disease activity were 
associated with a higher degree of bone mineral density (BMD) loss (71). Physical 
inactivity often as a result of severe disease with deformities and pain, also 
increases bone loss. 
Osteoporosis is also influenced by drug therapy in RA patients. Glucocorticoid use 
impacts on bone mineral density with a higher cumulative glucocorticoid dose being 
related to a lower BMD (72). Other risk factors for bone loss include radiological 
evidence of RA damage, older age and a lower body mass index (72). 
 
1.5 Summary 
Comorbidities in RA patients are common in industrialized populations. A multitude 
of comorbidities are seen affecting a number of organ systems. Comorbidities are a 
function of a number of factors including chronic inflammation, genetics, 
environmental influences, socioeconomic dynamics and drug therapy. Comorbid 
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diseases have a significant impact on patient outcomes, disability, expenditure, drug 
therapy, morbidity and mortality. As a result of their diverse and complex aetiologies, 
comorbidities in RA patients vary widely with geographical location. Understanding 
the spectrum of local comorbidities, their prevalence, impact and associated risk 
factors facilitates patient management. It also aids in allocating sparse resources by 
determining which patients to screen and how aggressively to manage comorbid 
diseases.  
 
1.6 Aims and objectives 
This study aims to determine the frequency of comorbidities in black South Africans 
with RA. Furthermore, it aims to describe the relationship between comorbid 
diseases and their associated risk factors. 
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2. CHAPTER 2: PATIENTS AND METHODS 
2.1 Patients 
A retrospective record review of RA patients attending the Arthritis Clinic of the Chris 
Hani Baragwanath Academic Hospital (CHBAH) between 1988 - 2015 was 
undertaken. The CHBAH is a tertiary hospital located in Soweto and serves the 
indigent population residing in the south of Johannesburg. This population is 
heterogeneous and is largely comprised of the middle to lower income subgroup. 
 
2.2 Criteria 
The following criteria were used: 
2.2.1 Inclusion criteria: 
- Patients older than 18 years of age 
- Patients fulfilling the 1987 (ACR) criteria for RA 
- Patients with established disease, defined as a follow up duration of ≥5 years 
- Black ethnicity, defined as all 4 grandparents being black South Africans 
2.2.2 Exclusion criteria: 
- Incomplete patient records 
 
2.3 Methods 
A convenient sample size of 500 patients were analyzed in the study. Patients were 
consecutively selected with records being kept in alphabetical order. Clinical data 
that was abstracted from the case records included: 
- Demographics: Age at last follow up, gender, smoking and follow up duration 
- Autoantibodies: RF and ACPA 
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- Extra-articular manifestations: Anaemia, nodulosis, scleritis, cutaneous 
vasculitis and ILD 
- Comorbid diseases: Cardiovascular, CNS, respiratory, infections, 
gastrointestinal, malignancies and osteoporosis 
- Drug therapy 
Data was transcribed onto data collection sheets (Appendix A) and captured onto the 
electronic data collection tool REDCap (Research Electronic Data Capture). 
 
2.4 Charlson comorbidity index 
The CCS was used as a measure of the cumulative burden of comorbid diseases. 
The comorbidities captured as part of the CCS are illustrated in Table 1.4. 
 
2.5 Definitions 
ACR functional class (FC)(73): 
 
1 – Able to perform self care, vocational and avocational activities. 
2 – Avocational activities limited. 
3 – Vocational and avocational limited. 
4 – Limited self care, vocational and avocational activities. 
Mild and severe disability was defined as a worst FC of 1-2 and 3-4 respectively. 
See appendix C for a full list of definitions. 
 
2.6 Statistical analysis 
Collected data was recorded, organized and analyzed using the following electronic 
aids: REDCap, Microsoft Office Excel 2007, MedCalc and STATISTICA version 12. 
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Normally distributed data (parametric data) were reported as means and standard 
deviations (SD). To compare categorical variables, the Pearson’s chi square test 
was used, and where appropriate the two tailed Fisher’s exact test was used. The 
Student’s T-test was used to compare means between independent groups. Non-
parametric data were expressed as medians and interquartile ranges (IQR). The 
Mann-Whitney test was used for non-parametric data.  
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3. CHAPTER 3: RESULTS 
3.1 Demographics, clinical features and therapy 
Table 3.1 depicts the demographics of the study population. Most patients were 
middle-aged to elderly females with long disease durations. The majority of patients 
tested were seropositive for either RF (91.0%) or ACPA (61.0%). 
Most patients had severe disability at the time of diagnosis (50.5%). The median FC 
(worst) was 3.0 (IQR 2.0-3.0). 
The commonest extra-articular manifestations (Table 3.2) are anaemia (78.2%) and 
subcutaneous nodules (31.0%). Other less common extra-articular features are 
scleritis, ILD and cutaneous vasculitis which were seen in 3.4%. 3.2% and 1.4% of 
patients respectively.  
With respect to medical therapy the majority of patients in the study had a history of 
using NSAIDs (98.8%), methotrexate (95.4%), other DMARDs (93%) and oral 
prednisone (85.8%). A small percentage of patients were treated with biologic agents 
(rituximab 2.6% and TNFi 1.0%) and cyclophosphamide (2.2%). 
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Table 3.1 - Demographics, autoantibodies and functional class of the 
study population 
Demographics Number 
Total number of patients 500 
Age, mean years (±SD) 60.0 (11.1) 
Female, (%) 435 (87) 
Male, (%) 65 (13) 
Female:Male 6.7:1.0 
Follow up duration, mean years (±SD) 10.7 (5.0) 
Symptom duration (prior to diagnosis), mean years (±SD) 5.1 (6.1) 
Autoantibodies Number (%), total 500 
Rheumatoid factor 455 (91.0) 
Anti-citrullinated peptide antibodies 305/376 (81.1) 
Functional Class (ACR) Number (%), total 500 
Worst  
1 6 (1.2) 
2 146 (29.2) 
3 277 (55.4) 
4 71 (14.2) 
Mean (IQR) 3.0 (2.0 - 3.0) 
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Table 3.2 - Extra-articular disease and drug therapy 
Extra-articular disease Number (%), total 500 
Anaemia: Current 194 (38.8) 
                 Past history 197 (39.4) 
                 Cumulative frequency 391 (78.2) 
Nodulosis 155 (31.0) 
Scleritis 17 (3.4) 
Interstitial lung disease 16 (3.2) 
Vasculitis 7 (1.4) 
Drug therapy Number (%), total 500 
History of non steroidal anti inflammatory drugs 494 (98.8) 
History of methotrexate 477 (95.4) 
Other non-biological disease modifying drugs 465 (93.0) 
History of prednisone 429 (85.8) 
Rituximab 13 (2.6) 
Cyclophosphamide 11 (2.2) 
TNFi  5 (1.0) 
 
3.2 Comorbidities 
Comorbidities occurred commonly in the study population with 98.0% of all patients 
having one or more comorbid diseases. The median number of comorbidities was 
3.0 (IQR 2.0 - 4.0). The median CCS was 3.0 (IQR 2.0 - 4.0) and when adjusted for 
age was 1.0 (IQR 1.0 - 2.0). This equated to a median 10 year survival rate of 77.0% 
(IQR 53.0% - 90.0%). Table 3.3 describes the frequency in which individual 
comorbid diseases occurred in the study population. Hypertension, 
hypercholesterolaemia, PUD, osteoporosis and serious infections were the most 
frequently occurring comorbid diseases. 
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Table 3.3 - Frequency of comorbidities 
Comorbidity Number (%), total 500 Comorbidity Number (%), total 500 
Gastro Intestinal:  Other:  
Peptic Ulcer Disease 73/114 (64.0) Moderate/Severe Renal Failure 33 (6.6) 
Liver Disease:  Mild 11 (2.2)   
                        Moderate/Severe 0 Non CCS comorbidities:  
  Hypertension 350 (70.0) 
Cardiovascular/CNS:  Hypercholesterolaemia 221/466 (47.4) 
Diabetes Mellitus 77 (15.4) Osteoporosis 62/132 (47.0) 
Congestive Heart Failure 33 (6.6) Serious Infections 56 (11.2) 
Cerebrovascular disease 14 (2.8) Tuberculosis 53 (10.6) 
Hemiplegia 7 (1.4) HIV 44/472 (9.3) 
Peripheral Vascular Disease 3 (0.6) History of Fractures 39 (7.8) 
Coronary Artery Disease 3 (0.6) Asthma 24 (4.8) 
  Hypothyroidism 13/459 (2.8) 
Respiratory:  Malignancy 9 (1.8) 
COPD 7 (1.4) Hepatitis: B 4/372 (1.1) 
                  C 6/372 (1.6) 
Infections:  Hyperthyroidism 3/459 (0.7) 
AIDS 3/472 (0.6)   
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3.2.1 Cardiovascular comorbidities 
Table 3.3 depicts the frequencies of cardiac comorbidities. A history of cigarette 
smoking was documented. A total of 20.8% (82/395) had a history of cigarette 
smoking. Of all the male patients studied 55.4% (36/65) had a history of cigarette 
smoking. In contrast only 10.6% (46/435) of females had a smoking history.  
Hypertension, hypercholesterolaemia and DM were found frequently. Despite the 
high frequency of CV risk factors, CAD was uncommon with a prevalence of 0.6%.  
3.2.2 Gastrointestinal comorbidities 
Only patients with clinically suspected PUD had undergone a gastroscopy (G-
scope). Of the 114 patients who had undergone a G-Scope the majority (64.0%) had 
a proven diagnosis of PUD. Liver disease was an uncommon finding in the study. 
3.2.3 Osteoporosis 
DEXA scans were done in those clinically suspected of having OP. Amongst the 132 
patients who had DEXA scans, OP was a common finding (47.0%).  
3.2.4 Serious infections 
Serious infections occurred commonly in the study population (11.2%). TB was 
noticeably prevalent with 53 patients (10.6%) having had the disease. Of note, none 
of these patients had been treated with TNFi. AIDS defining illnesses were 
uncommon in the HIV positive population. 
3.2.5 Respiratory comorbidities 
Non-infectious respiratory comorbidities like asthma, ILD and COPD were seen in 
4.8%, 3.2% and 1.4% of the population respectively. Amongst the patients 
diagnosed with COPD, 6 had a history of cigarette smoking and 5 were males 
(71.4%). The exact etiology and pattern of ILD amongst these patients was not 
explored. 
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3.2.6 Malignancies 
The following malignancies were documented:  
- Cervical carcinoma (3 patients)  
- Breast carcinoma (3 patients)  
- Prostate carcinoma 
- Renal cell carcinoma  
- Multiple myeloma 
Of note no lymphomas were recorded. 
 
3.3 Predictors of comorbidities 
Both increasing age (Figure 3.1) and a longer length of patient follow up was 
associated with a significant increase in the total number of comorbidities (p value 
<0.001 for both variables). In addition to age and length of follow up, disability was a 
function of the total number of comorbidities (Table 3.4). Of note, there was no 
relationship between markers of severe disease (seropositive disease, prednisone 
use and nodulosis) and the total number of comorbidities.  
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Table 3.4 - Predictors of comorbidities 
 Median number of 
comorbidities (IQR) 
P value (Mann-
Whitney test) 
Disability: 
- Mild 
- Severe 
 
2.00 (2.00 - 3.00) 
3.00 (2.00 - 4.00) 
 
<0.001 
Autoantibodies 
RF:      - Positive 
 - Negative 
ACPA: - Positive 
            - Negative 
 
-   3.00 (2.00 - 4.00) 
-   3.00 (2.00 - 4.00) 
-   3.00 (2.00 - 4.00) 
-   3.00 (2.00 - 4.00) 
 
0.603 
 
0.220 
Prednisone use: 
- Present 
- Absent 
 
-   3.00 (2.00 - 4.00) 
-   3.00 (2.00 - 4.00) 
 
0.952 
Nodulosis: 
- Present 
- Absent 
 
-   3.00 (2.00 - 4.00) 
-   3.00 (2.00 - 4.00) 
 
0.236 
 
 
Figure 3.1 - Scatter diagram depicting age and number of comorbidities 
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3.3.1 Disability and comorbidities 
Table 3.5 illustrates the comorbidities which were significantly associated with 
severe disability. Patients with markers of disease severity including a history of 
arthroplasty, rheumatoid nodules or prednisone use, were more likely to have severe 
disability. Furthermore, the relationship between ACPA positivity and disability as 
well as a history of scleritis and disability approached statistical significance with p 
values of 0.057 and 0.089 respectively.  
Table 3.5 – Relationship between disability and comorbid diseases 
 
ACR1-2, n (%)  ACR3-4, n (%)  
Odds Ratio (95% 
CI)  
P value 
(Fisher’s 
exact) 
Arthroplasty 7/152 (4.6) 66/348 (19.0) 4.85 (2.17 - 10.84) <0.001 
CCF  4/152 (2.6) 29/348 (8.3) 3.36 (1.16 - 9.74)  0.018  
Osteoporosis  9/152 (5.9) 53/348 (15.2) 2.52 (1.06 - 6.04)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.039
Serious 
infections  
9/152 (5.9) 47/348 (13.5)  2.48 (1.18 - 5.20)  0.013  
Prednisone 
use 
118/152 (77.6) 311/348 (89.4) 2.42 (1.45 - 4.04) <0.001 
History of 
anaemia 
104/152 (68.4)  287/348 (82.5)  2.17 (1.4 - 3.37)  <0.001 
Nodulosis 34/152 (22.4) 121/348 (34.8) 1.85 (1.19 - 2.87) 0.006 
Hypertension 96/152 (63.2) 254/348 (73.0) 1.58 (1.05 - 2.37)  0.034 
 
3.3.2 Associations with serious infections 
As noted in Table 3.6, patients with osteoporosis, vasculitis, anaemia, HIV, 
arthroplasty and longer disease durations were more likely to have had serious 
infections. 
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 Table 3.6 – Relationship between serious infections and comorbid diseases 
 
3.3.3 Associations with osteoporosis 
Patients who were diagnosed with OP were more likely to have had arthroplasty 
surgery than those without OP (prevalence of 30.6% and 10.0% respectively, 
Fischer’s exact two tailed p value of 0.013). 
 
3.4 Mortality 
There were 37 confirmed deaths noted in the study population during their follow up 
period. As depicted in Table 3.7, the deceased population had a high mean age and 
follow up duration (64.0 and 12.3 years respectively). Furthermore, the deceased 
 
Patients with serious 
infections, n (%) Odds Ratio (95% CI)  
P value 
(Fisher’s 
exact) 
Osteoporosis: 
- Present  
- Absent 
 
- 15/62 (24.2) 
- 4/70 (5.7) 
 
4.23 (1.48 – 12.08) 
 
0.003 
Vasculitis: 
- Present 
- Absent 
 
- 3/7 (42.9) 
- 53/493 (10.8) 
 
4.00 (1.63 – 9.73) 
 
0.034 
History of anaemia: 
- Present  
- Absent 
 
- 52/391 (13.3) 
- 4/109 (3.7) 
 
3.62 (1.34 – 9.80) 
 
0.005 
HIV status: 
- Positive 
- Negative 
 
- 10/44 (22.7) 
- 42/428 (9.0) 
 
2.32 (1.25 – 4.29) 
 
0.014 
Athroplasty: 
- Present 
- Absent 
 
- 15/73 (20.5) 
- 41/427 (9.6) 
 
2.14 (1.25 – 3.66) 
 
0.009 
Disease duration: 
- >10 years 
- ≤10 years 
 
- 34/213 (16.0) 
- 22/287 (7.7) 
 
2.08 (1.26 – 3.45) 
 
0.004 
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population had a significantly higher number of comorbidities (median of 4.0 [IQR 3.0 
- 5.0] vs 3.0 [IQR 2.0 - 4.0], Mann-Whitney p value <0.001) and a significantly higher 
FC than the living population (median 4.0 [IQR 3.0 - 4.0] vs 3.0 [IQR 2.0 - 3.0], 
Mann-Whitney p value <0.001). The CCI was significantly higher amongst the 
deceased as compared to the living (median of 0.77 [IQR 0.53 - 0.90] vs 0.21 [IQR 
0.15 - 0.59], Mann-Whitney p value <0.001), thus validating its clinical utility to 
predict mortality. The most common comorbidities amongst the deceased were PUD, 
anaemia, hypertension and serious infections. Although the exact causes of death 
were not confirmed by means of an autopsy, patient records were used to determine 
the most probable cause of death in 17 patients (see Table 3.8). 
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Table 3.7– Demographics, autoantibodies, functional class and 
comorbidities amongst the deceased 
Demographics Number 
Total number of patients 37  
Age at last visit, mean years ±SD 64.0 (10.7) 
Female, (%) 29 (78.4) 
Male, (%) 8 (21.6) 
Follow up duration, mean years (±SD) 12.3 (5.6) 
Symptom duration (prior to diagnosis), mean years (±SD) 5.1 (6.1) 
Autoantibodies Number (%) 
RF 34 (91.9) 
ACCP 7/10 (70.0) 
Functional Class (worst) Number 
Functional class, median (IQR) 4.0 (3.0 - 4.0) 
Comorbidities Number 
Number of comorbidities, mean ±SD 4.0 (1.5) 
CCS (age adjusted), mean ±SD 3.0 (1.5) 
PUD, n (%) 13/14 (92.9) 
Anaemia, n (%) 34 (91.9) 
Hypertension, n (%) 26 (70.3) 
Serious infections, n (%) 15 (40.5) 
Arthroplasty, n (%) 12 (32.4) 
CCF, n (%) 10 (27.0) 
Tuberculosis, n (%) 9 (21.6) 
Fractures, n (%) 6 (16.2) 
Malignancy, n (%) 2 (5.4) 
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Table 3.8 Causes of death 
Sepsis:  
- Pulmonary TB 
- TB with a drug induced liver injury 
- Community acquired pneumonia 
- Nosocomial pneumonia 
- Septicaemia 
- Colonic perforation with intra-
abdominal sepsis 
Pulmonary embolism 
Cervical cancer 
CCF 
Post TB bronchiectasis with 
decompensated cor-pulmonale 
COPD with decompensated  
cor-pulmonale 
ILD 
 
3.4.1 Comorbidities amongst the deceased 
Congestive cardiac failure, serious infections, ILD, arthroplasty, TB and PUD was 
more common amongst those who have demised during follow up (Table 3.9). In 
addition, more patients with a prior history of arthroplasty had demised.  
Table 3.9 – Common comorbidities and clinical features amongst the 
deceased 
 
Alive, number 
(%) 
Total 463 
Deceased, 
number (%) 
Total 37 
Odds ratio  
(95% CI) 
P value 
(Fisher’s 
exact) 
CCF 23 (5.0) 10 (27.0) 5.44 (2.80 – 10.55) <0.001 
Serious infections 41 (8.9) 15 (40.5) 4.58 (2.81- 7.45) <0.001 
ILD 16 (3.5) 5 (13.5) 3.91 (1.51 – 10.08) 0.014 
Arthroplasty 61 (13.2) 12 (32.4) 2.46 (1.46 – 4.14) 0.003 
TB 45 (9.7) 8 (21.6) 2.22 (1.13 – 4.36) 0.031 
PUD 60/100 (60.0) 13/14 (92.9) 1.54 (1.24 – 1.92) 0.012 
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4. Chapter 4: Discussion 
4.1 Demographic profile of black South African rheumatoid arthritis patients 
Rheumatoid arthritis occurs more commonly in females, amongst black South 
Africans. The female predominance noted in this study was larger than that 
described previously with a female to male ratio of 6.7:1. Even at presentation, the 
majority of patients had severe disability. This is in contradiction to earlier SA data 
demonstrating a milder course of the disease (3). Severe disability at presentation is 
possibly a consequence of the delay in seeking health care and a reflection of the 
barriers to accessing specialized health care in South Africa. On average, patients 
presented to the rheumatology department after being symptomatic for 5.13 years. 
Barriers to accessing health care include socioeconomic difficulties, as well as a lack 
of health care facilities and infrastructure. Addressing these barriers are important to 
ensure early treatment with DMARDs and thus preventing disability. 
 
4.2 Comorbidities in black South African rheumatoid arthritis patients 
Comorbidities in black South African RA patients are common with 98% of all 
patients having had one or more comorbid conditions. This is higher than that seen 
in European nations like the UK and Italy (78.6%)(24). Over a period of 15 years, 
Sam Norton (22) demonstrated in 2012 that 81% of RA patients in the UK had one or 
more comorbid conditions. Furthermore, not only are comorbidities more prevalent in 
black South African RA patients, but these patients also have a higher total number 
of comorbid illnesses. The median number of comorbidities in the study population 
equaled to 3.00 per patient. In comparison, in industrialized populations the median 
number of comorbidities equaled to 1.60 (22, 23). The high number of comorbid 
conditions seen in black SA patients is possibly a consequence of multiple factors 
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including poor socioeconomic conditions, limited access to health care facilities, 
delayed presentations, a high burden of infectious diseases, the frequent use of 
NSAIDs and glucocorticoids. Comorbid diseases worsen disability, increase mortality 
and increase economic expenditure (22, 26, 27). It is therefore vital for local treating 
physicians to place emphasis on, screen for and appropriately manage comorbid 
diseases in RA. 
4.2.1 Cardiovascular disease 
Hypertension was commonly seen occurring with a frequency of 70.0% (350/500). 
This is higher than that described in other industrialized nations and black non RA 
South Africans (25, 74, 75). A 2014 multi centric international cross sectional study 
by Dougados et al. (25) showed that hypertension occurred with a prevalence of 
39.0% (156/400) and 34.9% (15/43) in the USA and UK respectively. In that study 
the highest prevalence of hypertension was found in Hungary and Uruguay with a 
prevalence of 57.0% each.  
In addition to hypertension, a diagnosis of DM was common in the study population, 
occurring with a prevalence of 15.4% (77/500). In comparison, DM occurred with a 
frequency of 21.0% and 7.0% in USA and UK respectively (25). 
Hypercholesterolaemia was commonly found amongst black SA patients (47.4%, 
221/466). With regards to cigarette smoking, 20.8% (82/395) of patients had a 
history of cigarette smoking (past or present). This is lower than that described in 
first world countries with the prevalence of current cigarette smokers being 23% in 
both the USA and UK.  
Of the 500 patients studied, only 3 (0.6%) had a history of CAD. In comparison CAD 
occurred with frequencies of 5% and 2% in the USA and UK respectively (25).  
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Figure 4.1 – The geographical prevalence of cardiac risk factors and CAD 
Furthermore, the prevalence of cardiac risk factors differs between RA patients and 
the baseline non-RA black South African population (Figure 4.2). The non-RA data in 
this figure was extracted from black patients in the Heart of Soweto registry and 
studies carried out by Silwa K, et al (74, 75). These figures were based on a 
population referred to a specialized cardiac unit and are therefore likely to be an over 
estimate of the true burden of CVD and CV risk factors in South African patients. In 
addition, hypercholesterolaemia was defined as a total cholesterol value of 
>4.5mmol/l in this study. Despite this over estimation, the prevalence of 
hypercholesterolaemia and DM was still higher amongst the black RA population 
with non-RA figures in black patients equaling 39% and 9% for 
hypercholesterolaemia and DM respectively. The prevalence of hypertension 
amongst black females was 61.9% (74).  Given the above, the prevalence of CAD 
paradoxically remained lower in black RA patients (0.6%) as opposed to black non-
RA South Africans (10.0%). 
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Figure 4.2 – The prevalence of cardiac risk factors and CAD amongst RA 
and non RA South Africans (74, 75) 
The underlying mechanism for the high prevalence of hypertension amongst black 
RA patients remains illusive. The common use of NSAIDs (98.8%) and 
glucocorticoids (85.8%) may be a possible contributory factor to the development of 
hypertension. Furthermore, the low prevalence of CAD in black South African RA 
patients suggests that some degree of protection is conferred in this population. The 
exact nature of this protective relationship is unknown and may be influenced by a 
combination of disease process itself, genetics, lower levels of central obesity and 
lower levels of systemic IL-6 (76). More research is needed to better define this 
relationship. 
4.2.2 Osteoporosis 
Osteoporosis occurred commonly (42%, 62/132). Performing DEXA scans on all RA 
patients in developing nations is challenging considering financial and other resource 
constraints. Undiagnosed and untreated, OP increases the likelihood of 
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complications like fragility fractures and the need for arthroplasty amongst patients 
with OP (see section 3.3.3). Thus, undiagnosed OP has both financial implications 
as well as an impact on morbidity, mortality and quality of life. These costs may 
offset the costs of performing DEXA scans. It is thus prudent to allocate resources 
efficiently and as such further data is needed amongst local RA patients to help 
identify those at risk and those needing further screening. 
4.2.3 Serious infections 
Serious infections occur commonly amongst RA patients (11.2%, 56/500) and are 
significantly more common in HIV positive patients. Tuberculosis is of particular 
concern in the local South African setting. Patients with OP, vasculitis, anaemia, HIV, 
orthopaedic surgery and longer disease durations, are at a higher risk of developing 
serious infections. As a result, these patients should be monitored more closely. The 
burden of infectious diseases is further amplified by the use of immunosuppressive 
agents and biologic DMARDs. Treating clinicians should thus individualize treatment 
by weighing the benefits of therapy with local infection risk profiles. Further local data 
will assist in facilitating this therapeutic decision making process.  
 
4.3 Mortality 
In our study population, mortality was found to be a function of age, severity of 
disability and the number of comorbid diseases. This further illustrates the 
importance of screening for and appropriately managing comorbidities in RA 
patients. A history of CCF, serious infections and ILD conferred the highest risk of 
mortality amongst black South African RA patients. This is similar to that seen in 
industrialized countries. Data from the UK by Ogdie et al has shown that CVD, 
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respiratory disease, malignancies and infections were the most common causes of 
death (77).  
4.4 Limitations 
The inherent retrospective nature of the study means that the accuracy is reliant on 
availability of data in patient’s files. Incomplete, missing or inaccurately completed 
files affect the quality of data. The extents to which comorbidities are investigated for 
by attending clinicians also limit the quality of the data. Most comorbid conditions are 
investigated for, on the basis of clinical suspicion and not on the basis of routine 
screening thus resulting in the under diagnosis of comorbid conditions. 
The high prevalence of anaemia in the study population may have influenced HbA1c 
values thus affecting the true prevalence of DM. With regards to OP, the influence of 
hyperparathyroidism was not accounted for. 
Post mortem autopsies were not carried out on deceased patients, thus the cause of 
death could not be determined with certainty. The causes of death amongst patients 
were the most likely or presumptive cause of death. The impact of terminal events 
and diseases were therefore not accurately determined. 
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5. Chapter 5: Conclusion 
Comorbidities in black South African RA patients are common with a high average 
number of comorbidities seen. The spectrum of comorbid diseases varies 
geographically. This holds true amongst black SA patients in which a unique 
comorbid disease profile exists. Hypertension occurs commonly amongst these 
patients. Its precise etiology however, remains unknown. In addition to hypertension, 
other cardiac comorbidities and risk factors are also common. Despite this, the 
prevalence of CAD still remains low. The exact protective mechanism against CAD is 
unknown. 
South African clinicians face unique challenges in the management of RA. The high 
burden of serious infections needs to be considered in the management of patients 
with particular regards to immunosuppressive therapy. Resource limitations demand 
the efficient and appropriate use of available investigative tools. Thus data 
concerned with comorbid diseases assists in identifying patients at risk and 
facilitates the efficient allocation of scarce resources. The common finding of 
osteoporosis amongst the study population suggests that more intensive screening 
should be considered in RA patients. Despite its limitations (section 4.4), this study is 
to our knowledge the largest cohort undertaken to investigate comorbid diseases in 
black South African RA patients.  
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Appendix A – Data collection sheet (established using REDCap) 
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Comorbidities
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Appendix B – Definitions 
 
Cardiovascular risk factors: 
- Hypertension: systolic blood pressure of ≥140mmHg or a diastolic blood 
pressure of ≥90mmHg or on antihypertensive medication (78). 
- Diabetes Mellitus: fasting glucose level of ≥7mmol/l, a glycated haemoglobin 
A1c of ≥6.5%, a random plasma glucose of ≥11.1mmol/l with symptoms or 
already on an oral hypoglycaemic agent or insulin (79).  
- Hypercholesterolaemia: A total cholesterol level of ≥5.0mmol/l.  
Cardiovascular disease: 
- Myocardial infarction: Patients with one or more definite or probable events 
defined as a hospitalization for chest pain with electrocardiographic and/or 
enzyme changes (29).  
- Congestive cardiac failure: Patients with exertional dyspnea or paroxysmal 
nocturnal dyspnea who have responded symptomatically or clinically to 
treatment (29). 
- Peripheral vascular disease: A history of intermittent claudication, bypass 
surgery for arterial insufficiency, gangrene, acute arterial insufficiency, 
thoracic aneurysm or abdominal aneurysm (29). 
- Cerebrovascular disease: A history of a haemorrhagic or ischaemic stroke 
with minor or no residual weakness or a transient ischaemic attack (29). 
- Hemiplegia: Hemiplegia or paraplegia as a result of a cerebrovascular 
accident or other pathology (29). 
Anaemia: 
- Males – Haemoglobin level of <14.3g/dL (based on local laboratory reference 
values). 
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- Females – Haemoglobin level of <12.1g/dL (based on local laboratory 
reference values). 
Osteoporosis: A DEXA T-score of less than -2.5 SD (80). 
Moderate to severe kidney disease: Defined by a glomerular filtration rate 
(GFR) of ≤60mL/min/1.73m² or patients on dialysis, those who have had a 
kidney transplant and those with uraemia (81). 
Serious infections: Any infection requiring hospital admission or intravenous 
antibiotic therapy. 
Gastrointestinal: 
- Peptic ulcer disease and gastritis: Based on gastroscopic evidence of 
disease. 
- Liver disease: Mild liver disease includes chronic infection with hepatitis B or 
C or cirrhosis without evidence of portal hypertension. Moderate liver disease 
includes cirrhosis with portal hypertension (non-variceal bleeding). Severe 
liver disease consists of ascites, jaundice, portal hypertension, variceal bleeds 
or a liver transplant (29). 
Pulmonary disease:  
- COPD: the presence of compatible symptoms and spirometry showing airflow 
limitation (a forced expiratory volume after 1 second / Forced vital capacity 
(FVC) ratio of <0.7 and a FEV1 of <80% of predicted) (82). 
- Asthma: A history of intermittent typical symptoms, demonstration of variable 
airflow limitation by spirometry and exclusion of alternative diagnoses. 
Malignancies: Any solid or haematological cancer will be recorded. 
Dementia: Patients with moderate to severe cognitive deficit with impaired 
function from any cause (29). 
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